Chan Lee Biography and Net Worth

SVP of BeOne Medicines

Chan Lee joined BeiGene as General Counsel in July 2022.

Mr. Lee previously worked at Sanofi from 2016 to 2022, where he served as North America General Counsel and Head of Legal for the Specialty Care Global Business Unit, responsible for the legal oversight of the company’s U.S. and Canada businesses and its global Specialty Care business. Prior to Sanofi, he held roles of increasing responsibility from 2008 to 2016 at Pfizer, most notably as Chief Counsel for Pfizer’s Innovative Health global business, and, earlier, as Chief Counsel for the Vaccines, Oncology and Consumer Health global businesses, and as Assistant General Counsel for Asia.

Mr. Lee earned his J.D. from the University of California at Berkeley and his B.S. in applied economics from Cornell University.

How do I contact Chan Henry Lee?: The corporate mailing address for Lee and other BeOne Medicines executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. BeOne Medicines can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Chan Henry Lee's contact information.
Has Chan Henry Lee been buying or selling shares of BeOne Medicines?: During the last ninety days, Chan Henry Lee has sold $4,086,891.72 in shares of BeOne Medicines stock. Most recently, Chan Henry Lee sold 996 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a transaction totalling $347,773.32. Learn More on Chan Henry Lee's trading history.
Who are BeOne Medicines' active insiders?: BeOne Medicines' insider roster includes Chan Lee (SVP), John Oyler (CEO), Aaron Rosenberg (CFO), Corsee Sanders (Director), Corsee Sanders (Director), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeOne Medicines' active insiders.
Are insiders buying or selling shares of BeOne Medicines?: In the last twelve months, insiders at the sold shares 51 times. They sold a total of 1,475,419 shares worth more than $391,016,020.22. The most recent insider tranaction occured on November, 26th when Director Corazon (Corsee) D Sanders sold 2,627 shares worth more than $895,544.30. Insiders at BeOne Medicines own 6.6% of the company. Learn More about insider trades at BeOne Medicines.
Information on this page was last updated on 11/26/2025.

Chan Henry Lee Insider Trading History at BeOne Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/12/2025	Sell	996	$349.17	$347,773.32
10/8/2025	Sell	10,671	$350.40	$3,739,118.40
9/10/2025	Sell	10,006	$325.53	$3,257,253.18
8/13/2025	Sell	11,013	$300.45	$3,308,855.85
7/30/2025	Sell	920	$304.60	$280,232.00
6/16/2025	Sell	422	$266.50	$112,463.00
6/6/2025	Sell	700	$256.11	$179,277.00
2/21/2025	Sell	1,202	$258.04	$310,164.08

Chan Henry Lee Buying and Selling Activity at BeOne Medicines

BeOne Medicines Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $331.40

$330.98

$340.98

50 Day Range

MA: $332.91

$308.22

$377.47

2 Week Range

Now: $331.40

$170.99

$385.22

Volume

239,751 shs

Average Volume

310,848 shs

Market Capitalization

$39.28 billion

P/E Ratio

649.80

Dividend Yield

N/A

Beta

0.45